Product Description
Mechanisms of Action: SP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea | Taiwan | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Yonsei University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Gabexate](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Small Cell Carcinoma|Liver Failure, Acute|Hepatocellular Carcinoma|Sepsis|Reperfusion Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR-IPR-14005518 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2017-12-31 |
|
NCT02710266 | P3 |
Terminated |
Liver Failure, Acute|Sepsis|Small Cell Carcinoma|Hepatocellular Carcinoma|Reperfusion Injury |
2017-02-25 |